Tivic health extends its worldwide license of tlr5 agonist entolimod to include the treatment of neutropenia

Fremont, calif.--(business wire)--tivic health systems, inc. (nasdaq: tivc), a diversified therapeutics company, today announced that, on march 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance entolimod™ for a second indication, neutropenia. this expansion of commercial rights is part of the license agreement with statera biopharma for its late-stage toll-like receptor 5 (tlr5) immunotherapy program entolimod™. neutropenia is a condition characterized b.
TIVC Ratings Summary
TIVC Quant Ranking